North America Cell and Gene Therapy CDMO Market Size, Share By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4) and By Country - Trends, Analysis, and Forecast till 2034

North America Cell and Gene Therapy CDMO Market was valued at USD 2.5 Billion in 2024 and is expected to reach USD 30.1 Billion by 2034 growing at a CAGR of 28.9%

The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market stands at the forefront of transformative healthcare innovations, poised to revolutionize the treatment landscape for a myriad of diseases. As the demand for personalized medicine grows and the potential of cell and gene therapies becomes increasingly evident, the role of CDMOs becomes indispensable. These organizations play a pivotal role in bridging the gap between research and commercialization, offering specialized expertise and infrastructure for the development and manufacturing of cell and gene therapies. With a focus on scalability, quality assurance, and regulatory compliance, CDMOs enable biopharmaceutical companies to bring their therapies from concept to market with efficiency and confidence. In this dynamic landscape of breakthrough therapies and evolving regulatory frameworks, the Cell and Gene Therapy CDMO market represents a nexus of innovation, collaboration, and opportunity, poised to drive transformative advancements in healthcare for years to come.

Key Drivers of Target Market:

The Role of Rare Diseases

The rising prevalence of genetic and rare diseases stands as a pivotal driving force propelling the growth of the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market. As awareness of these conditions increases, so does the demand for innovative treatments capable of addressing their underlying genetic causes. Cell and gene therapies offer promising avenues for intervention by targeting and correcting genetic abnormalities at their source, potentially providing long-term or curative benefits for patients. In response to this demand, biopharmaceutical companies are increasingly turning to CDMOs for their specialized expertise in developing and manufacturing these advanced therapies. CDMOs play a crucial role in advancing the development and commercialization of cell and gene therapies, offering end-to-end services including process development, manufacturing, and quality assurance, thereby facilitating the efficient and effective delivery of these life-changing treatments to patients in need.

Technological Advancements

A significant market driving factor for the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is the continuous advancement of technology. Technological innovations play a pivotal role in enhancing the development, manufacturing, and commercialization processes of cell and gene therapies, making them more efficient, scalable, and cost-effective. Advanced technologies such as automation, high-throughput screening, gene editing tools (e.g., CRISPR-Cas9), and viral vector production systems have revolutionized various aspects of cell and gene therapy development, allowing for faster and more precise manufacturing processes. These technological advancements not only streamline production but also improve product quality, consistency, and safety. Additionally, innovative digital platforms and analytics tools enable CDMOs to optimize process parameters, monitor manufacturing workflows in real time, and ensure compliance with regulatory requirements. As a result, the integration of cutting-edge technologies empowers CDMOs to meet the growing demand for cell and gene therapies, drive innovation in the field, and ultimately accelerate the delivery of transformative treatments to patients worldwide.

Restrains:

Lack of Skilled Workforce

A notable restraining factor for the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is the challenge posed by a lack of skilled workforce. The specialized nature of cell and gene therapy manufacturing requires highly trained personnel with expertise in cell biology, molecular biology, bioprocessing, and other relevant fields. However, there is a scarcity of professionals with the necessary skill sets and experience to effectively navigate the complex manufacturing processes and regulatory requirements associated with these advanced therapies. As a result, CDMOs may struggle to recruit and retain qualified talent, which can impede their ability to scale operations, meet project timelines, and maintain consistent product quality. Furthermore, the shortage of skilled workforce may lead to increased labor costs and delays in project execution, ultimately affecting the competitiveness and growth potential of CDMOs in the cell and gene therapy market. Addressing this workforce challenge through targeted training programs, collaboration with academic institutions, and talent development initiatives is crucial for overcoming this restraining factor and unlocking the full potential of the cell and gene therapy CDMO market.

The market is segmented based on Service Area, Indication, Phase and Country.

North America Cell and Gene Therapy CDMO Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2023 to 2034. For the purpose of this study segmented the North America Cell and Gene Therapy CDMO Market report based on Service Area, Indication, Phases and Country:

Segmentation:

By Service Area:

• Cell Therapy

• Plasmid DNA
• Viral Vector
• Others    

By Indication:

• Cancer
• Cardiovascular Disease
• Infectious Disease
• Genetic Disorders
• Neurological Disorders

By Phases:

• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Country:

• U.S.
• Canada

The key players operating the North America Cell and Gene Therapy CDMO Market includes Catalent Inc., LONZA GROUP, RECIPHARM AB, Wuxi Advanced Therapies, Pfizer CentreOne, Charles River Laboratories International Inc., PATHEON INC., Almac Group, and FUJIFILM DIOSYNTH BIOTECHNOLOGIES, PCI Pharma Services.

• Catalent Inc. 
• LONZA GROUP
• RECIPHARM AB
• Wuxi Advanced Therapies
• Pfizer CentreOne
• Charles River Laboratories International Inc.
• PATHEON INC., INC.
• Almac Group
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• PCI Pharma Services